Physician profile
Robert W Later
NPI 1669567376
$1,960.29
in general payments reported to CMS, 2019-2025
25 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.17 · 2020: $118 · 2021: $264 · 2022: $440 · 2023: $434 · 2024: $475 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.32 |
| Education | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.58 | 2019-2025 | |
| Astellas Pharma US INC | $351.79 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $167.90 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $125.71 | 2022-2023 | Nexletol, Contrave, Nexlizet |
| Mayne Pharma Commercial LLC | $101.01 | 2021-2025 | |
| Exeltis, USA INC. | $83.78 | 2021-2023 | Slynd |
| Hologic Sales and Service, LLC | $79.13 | 2021-2023 | Aptima |
| Idorsia Pharmaceuticals US INC | $57.45 | 2023 | Quviviq |
| Therapeuticsmd, INC. | $53.32 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $46.60 | 2022-2023 | Seglentis |
| Lupin INC. | $43.82 | 2019-2020 | |
| Becton, Dickinson and Company | $34.40 | 2021-2022 | |
| Avion Pharmaceuticals | $32.75 | 2022 | |
| Shield Therapeutics INC | $31.48 | 2023-2024 | Accrufer |
| Pfizer INC. | $28.36 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.89 | 2020 | |
| Biogen, INC. | $22.71 | 2024 | |
| Meditrina | $22.14 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $20.52 | 2021 | |
| Sumitomo Pharma America, INC. | $17.00 | 2025 | Myfembree |
| Hologic INC | $15.29 | 2021 | |
| Lilly USA, LLC | $14.10 | 2023 | Zepbound |
| Bausch Health US, LLC | $13.94 | 2022 | |
| Virtus Pharmaceuticals LLC | $12.45 | 2021 | |
| Allergan, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Later listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.